May 17, 2018
SNMMI Value Initiative Industry Alliance co-chaired by Jonathan Allis, DPhil, CEO of Blue Earth Diagnostics, and James Williams, PhD, Head of Siemens Healthineers Molecular Imaging
RESTON, Va. – The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Value Initiative Industry Alliance brings members of the corporate community to the table as key players in building the future of nuclear medicine and molecular imaging and demonstrating to the medical community, regulators, patients and the public their crucial role in delivering the highest quality of care.
The Industry Alliance will help implement SNMMI’s Value Initiative, which provides the vision for, and forms the basis of, the society’s new strategic plan and focuses on five key domains: Quality of Practice, Research and Discovery, Workforce Pipeline, Advocacy and Outreach.
Value Initiative Industry Alliance corporate members will help shape the field’s future by providing funding support, strategic industry guidance and collaborative knowledge-sharing. The Industry Alliance is led by an Advisory Committee, which is co-chaired for 2017-2018 by
“SNMMI is proud to work with these industry leaders and their companies, and honored to strengthen that collaboration through the Value Initiative Industry Alliance,” said SNMMI Vice President Satoshi Minoshima, MD, PhD, who chairs the Value Initiative Board. “Innovative nuclear medicine and molecular imaging research is beginning to transform precision medicine and patient outcomes. Working together with Alliance participants, which range from small businesses to the largest corporations in the industry, we can advance scientific discoveries and rapidly translate them to patient care with more effective diagnostics and targeted therapy.”
“As a manufacturer of both PET scanners and PET radiopharmaceuticals, Siemens Healthineers Molecular Imaging relies on our relationship with the SNMMI to support, expand and develop the role of PET in clinical imaging, and on research efforts like the Clinical Trials Network to expand the future scope of nuclear medicine” said James Williams, PhD.
“In the past four years, Blue Earth Diagnostics has partnered closely with the SNMMI on a range of activities supporting the development and commercial introduction of Axumin® (fluciclovine F 18), our FDA-approved PET imaging agent, in the United States,” said Jonathan Allis, DPhil, CEO of Blue Earth. “Of particular value is our partnership with SNMMI on training readers how to optimally interpret Axumin scans. We hope, via the Value Initiative, to allow other companies to benefit from and to contribute to the growth of nuclear medicine.”
Alliance work is already underway, and members, including representatives from Leadership Circle participants Blue Earth Diagnostics, Siemens Healthineers Molecular Imaging, Jubilant DraxImage Inc., and Advanced Accelerator Applications (AAA), will meet during SNMMI’s Annual Meeting in Philadelphia, Pennsylvania, June 23-26, 2018.
For more information on SNMMI’s Value Initiative Industry Alliance, please contact Virginia M. Pappas, CAE, SNMMI CEO, 703-326-1181 email@example.com. To learn more about molecular imaging and personalized medicine, please visit the SNMMI Media Center.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising awareness about nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 15,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.
About Siemens Healthineers
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.
In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide. Further information is available at: www.siemens-healthineers.com.
About Blue Earth Diagnostics
Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics is backed by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.